Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects
Clinical trial NCT02156466 · COMPLETED
Trial details
- NCT number
- NCT02156466
- Sponsor
- Merck KGaA, Darmstadt, Germany
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-08-01
- Primary completion
- 2015-08-01
- Enrollment
- 41
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.